NCT03385850 is a NA clinical trial of enteral nutrition in Sepsis, sponsored by Nanjing First Hospital, Nanjing Medical University.

Who is sponsoring NCT03385850?

NCT03385850 is sponsored by Nanjing First Hospital, Nanjing Medical University.

What drugs are being tested in NCT03385850?

Interventions in NCT03385850: enteral nutrition.

What condition does NCT03385850 study?

NCT03385850 studies Sepsis, Immune System Disorder, Enteral Feeding.

Is NCT03385850 still recruiting?

NCT03385850 is currently completed. Last updated 5 March 2019.

Last reviewed 2019-03-05 · How we verify

NCT03385850

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Th17/Treg Cells and IL-23/IL-17 Axis and Early Enteral Nutrition in Sepsis

Completed NA Last updated 5 March 2019

What this trial tests

NA trial testing enteral nutrition in Sepsis in 53 participants. Completed in 31 December 2018.

Timeline

1 October 2017

Primary endpoint
30 June 2018

31 December 2018

Quick facts

Lead sponsor	Nanjing First Hospital, Nanjing Medical University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	53
Start date	1 October 2017
Primary completion	30 June 2018
Estimated completion	31 December 2018
Sites	1 location across China

Drugs / interventions tested

enteral nutrition — full drug profile →

Conditions studied

Sepsis — all drugs for Sepsis →
Immune System Disorder — all drugs for Immune System Disorder →
Enteral Feeding — all drugs for Enteral Feeding →

Sponsor

Nanjing First Hospital, Nanjing Medical University

Who can join

Adults 18 to 70, any sex, with Sepsis or Immune System Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators aim to evaluate the roles of Th17/Treg cells and IL-23/IL-17 axis in the mechanisms of early enteral nutrition (EEN) correcting immune imbalance of sepsis by means of improving the intestinal flora disturbance. The results of this study would lay the foundation for revealing the mechanisms of EEN improving immune imbalance of sepsis and provide a new idea to the early treatment of sepsis

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effects of early enteral nutrition on Th17/Treg cells and IL-23/IL-17 in septic patients.
Sun JK, Zhang WH, Chen WX, Wang X, et al · · 2019 · cited 31× · PMID 31236002 · DOI 10.3748/wjg.v25.i22.2799

Verify or expand the search:

Other trials of enteral nutrition

Trials testing the same drug.

NCT07411014 — Enteral Versus Parenteral Nutrition During Recovery After Shock · NA · not yet recruiting
NCT07001943 — Correlation Study Between SMA Blood Flow Reactivity and Acute Gastrointestinal Injury in Critically Ill Patients · recruiting
NCT06673134 — Prospective Cohort Establishment and Clinical Observation of Children With Crohn's Disease · active not recruiting
NCT05900167 — Feeding Intolerance Risk Prediction Model in Patients With Enteral Nutrition Through Nasogastric Tube · unknown
NCT06828094 — Enteral Nutrition and Immune Proteins Study · NA · active not recruiting

Other recruiting trials for Sepsis

Currently open trials in the same condition.

NCT07507877 — Infraclavicular Axillary Vein Collapsibility Index as a Predictor of Fluid Responsiveness · recruiting
NCT07154615 — Assessing Immune Dysfunction in Sepsis · recruiting
NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
NCT07351344 — African Survey on Sepsis Knowledge (ASK) · recruiting
NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting

Other Nanjing First Hospital, Nanjing Medical University trials

Trials by the same sponsor.

NCT07349979 — PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy · NA · not yet recruiting
NCT07505056 — Jianpi Lishi Jiedu Granules for Prevention of Postoperative Recurrence in Colorectal Advanced Adenomas · Phase 3 · not yet recruiting
NCT07397234 — Thyroid Cartilage Plane VS Superior Laryngeal Nerve Space Block in Awake Tracheal Intubation · NA · not yet recruiting
NCT07455448 — Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study · completed
NCT07385885 — Ultrasound-guided Non-invasive Simulation in Anesthesia Residency Training · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03385850 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nanjing First Hospital, Nanjing Medical University
Last refreshed: 5 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03385850.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing